Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Tm, That is the information I'm using to form my opinion. They give us the baseline numbers, then say that they will provide results at the conference.
Sleven,
Monk, I work with the information that I can find. We have a presentation number. (Lp019). We have a description of the presentation. (Results). That is the extent of the information we have. If someone could find a link to the actual presentation that would give us more information to work with. At this point I am making the assumption that the trial failed. This is not definitive. It is also not a "humble" opinion. I am waiting for a response from the trial coordinator.
Sleven,
Captain, Zip, The information that we have points to the conclusion that top line results were released at the CTAD conference. We should assume that the study did not achieve successful results. We don't know this definitively.
Sleven,
Exwannabe, That is possible. I emailed the study coordinator with an information request. If she responds I will let people know what she has to say.
Sleven,
Laurent, without having a link to the presentation we don't know what it covered. I posted this with the Hope that someone can find a link to the presentation.
Sleven,
Shadolane, I couldn't find the results either. It does look like they have been presented. Hopefully someone here can find them. I am going to assume that BRAVE failed to meet primary and secondary endpoints. I have reached out to the study coordinator with a request for information.
Sleven,
Lp019/BRAVE/CTAD
October 27, 2023
Sleven,
CBB, interesting reply.
Sleven,
CBB, I understand your opinion. The clinical scientific community has made a decision on how to evaluate Vascepa in relationship to Cancer. I'm going to take their opinion over yours.
Sleven,
CBB, Have you ever entertained the notion that Amarin is simply going to run this company and increase revenue without selling out?
Sleven,
CBB,
https://clinicaltrials.gov/search?cond=Cancer&term=Vascepa
Here are the current cancer related studies.
Sleven,
CBB, It can't be a priority at the moment. That's a financial issue. The studies being conducted right now are looking at icosapent ethyl as a primary treatment. From memory I think the metastasized breast cancer study might have a secondary drug involved. The CVD indication that we have is worth more than most understand. These other indications will play out over time. I don't think this company is up for sale at the moment.
Sleven,
CBB, You are aware that there are several ongoing studies, of Vascepa, for cancer patients?
Sleven,
Captain, Thanks for the numbers. The new NICE guidelines should be helpful.
Sleven,
Anilkhera, Nice find. Thanks.
Sleven,
Nuke, I'm not forgetting anything. My interest beyond the share price is what is the company doing. Under the new board the company is doing nothing differently. I don't care how they aquire shares.
Sleven,
Jasbg, At this point there is no productive reason to post negative opinions about Sarissa capital. That's why I don't. I posted some unflattering information about Alex Denner before the proxy vote. No one cared. The torches were lit and the villagers on the march. It's possible that some posters are saying "I told you so". I might have something to say before the next annual meeting.
My question to you was, what exactly has this new board done to improve the position that Amarin is in.
Sleven,
Jasbg, Why do you have such unwaivering trust in Sarissa capital? What exactly has Sarissa/Denner done since taking control of the company? Lot's of promises where made. One of them was greater transparency.i can assure you that under this new board that has actually gotten worse. None of my questions ever get a response. I am a believer in the value of our product not the management of Sarissa capital.
I voted against them.
Sleven,
https://www.sciencedirect.com/science/article/abs/pii/S0889159123001150
If this has been posted before, my apologies.
Sleven,
North, Not yet. I checked this morning. I don't know how long it usually takes from the last brief filed to the arguments. I will keep checking. As soon as i see us on the schedule I will let you know.
Sleven,
Zip, Let's hear it for the UK.
Sleven,
https://www.england.nhs.uk/long-read/items-which-should-not-routinely-be-prescribed-in-primary-care-policy-guidance/
This should help sales in the UK.
Sleven,
JRoon, I think we should keep our eyes on that website this week.
Sleven,
JRoon, When I asked I was told that they would release the results on the CTG website.
Sleven,
Zip, Don't know. I. Would assume that that the update had a reason.
Sleven,
JRoon, That's my line of thought.
Sleven,
JRoon, Yes. Tha status is now completed.
Sleven,
https://fluidsbarrierscns.biomedcentral.com/articles/10.1186/s12987-020-00230-3
For anyone interested.
Sleven,
Pdude, Thanks for the detailed explanation of the subtle difference in the cerebral vascular system. My comments where focused on the primary outcome of increased blood flow in cerebral arteries. I am assuming that the inner surface of the cerebral vascular system is the same as the rest of the cardiovascular system. Is this incorrect? Do you know what causes the BBB?
Thanks.
Sleven,
North, I don't think the vascular system in the brain is different than any other part of the body.
Sleven,
Nuke, I can't sign in either.
Sleven,
JRoon, Thanks.
Sleven,
MSB, Do you have a link to this information?
Sleven,
Denisk, ( If they increase sales to $100k per quarter they should be able to generate $20 million of cash per quarter.) Have you had a stroke? You are also starting in absolute terms that you believe positive clinical trial results have no effect on the PPS of biotech companies?
Sleven,